LUNG - pulmonx.com Debt to Book Capitalization Ratio

Pulmonx Corporation (LUNG) operates in a defensive sector where demand for COPD therapy remains stable regardless of economic cycles. The historical debt-to-book capitalization ratio visualizes this resilience, with 1.52 serving as the base value of the parameter. The business relies on robust health insurance with minimal seasonality, while stringent FDA requirements and patents create a powerful barrier to entry for new players.

Pulmonx Corporation demonstrates high patient loyalty thanks to its unique Zephyr valve implantation system. This indicator compares total liabilities to the amount of equity to assess financial leverage. By analyzing changes in the ratio of total debt to book capitalization, an investor determines whether borrowings create a critical risk during a decline in profits. The metric reveals the extent to which business stability depends on external financing. The stability of this ratio confirms the reliability of long-term share price growth.